Background Effective immunosuppression through optimization of trough levels tacrolimus
reduces post-transplant mortality rate in liver transplant cases. Methods Meta-analysis was …

The aim of this study was to investigate whether the heterogeneity in tacrolimus dose
requirement is associated with ABCB1 and CYP3A5 gene polymorphisms in Chinese liver …

Background The effects of multidrug resistance-1 (MDR1), ABCC2, and P450
oxidoreductase (POR)* 28 gene polymorphisms on tacrolimus metabolism following a …

Background: Tacrolimus (TAC) is an immunosuppressant used in organ transplant
recipients. It is a substrate of drug transporter ABCB1 as well as of cytochrome P4503A …

Studies of liver transplant (LT) patients, mainly in Asians, have evaluated the influence of the
CYP3A5* 1 allele and P‐glycoprotein gene ABCB1 on tacrolimus pharmacokinetics or …

Background: Tacrolimus pharmacokinetics has large inter-individual variability. Objectives:
This study aimed to investigate the impact of donor and recipient gene polymorphisms on …

Background: Tacrolimus is a substrate of cytochrome P-450 (CYP) 3A enzyme and of the
drug transporter ABCB1. We have investigated the effects of possible relevant CYP3A5 and …

Objectives: Previous studies have reported reduced tacrolimus dose-adjusted exposure in
individuals expressing the CYP3A5* 1 allele (reference singlenucleotide polymorphism …

BACKGROUND The aim of the present study was to investigate the pharmacokinetics of the
once-daily tacrolimus formulation (QD form) in relation to polymorphisms of the donor …

Objectives: Tacrolimus is widely used as an immunosuppressive drug in liver transplant
recipients with a narrow therapeutic range and variable individualized pharmacokinetics …